Search Immortality Topics:

Page 6«..5678..2030..»


Category Archives: Biotechnology

Is Zai Lab Ltd – ADR (ZLAB) a Winner in the Biotechnology Industry? – InvestorsObserver

Is Zai Lab Ltd - ADR (ZLAB) a Winner in the Biotechnology Industry?  InvestorsObserver

Originally posted here:
Is Zai Lab Ltd - ADR (ZLAB) a Winner in the Biotechnology Industry? - InvestorsObserver

Posted in Biotechnology | Comments Off on Is Zai Lab Ltd – ADR (ZLAB) a Winner in the Biotechnology Industry? – InvestorsObserver

The View from ARK Invest: A Discussion with Simon Barnett and Ali Urman – Genetic Engineering & Biotechnology News

[ Click the lower right icon to view fullscreen with transcript ^ ]

During the recent biotechnology financing boom, investors pumped billions of dollars into startups across specialties ranging from cell and gene therapy to cancer immunotherapy and CRISPR genome editing. But that boom has given way to a bear market in the past year.

Simon Barnett and Ali Urman are senior analysts with ARK Invest, an investment management firm that specializes in public companies with a bent for innovation. Because public markets remain dry, ARK is now also looking to invest in private companies as well.

In this discussion with GENs Fay Lin, PhD, and Alex Philippidis, Simon Barnett and Ali Urman explain how ARK Invest came to focus on disruptive public companies, how the firm approaches advancing innovation in its portfolio companies, and their search for startups with promising technologies and enough business expertise to commercialize them. The pair also describes how the new ARK Innovation Center in St. Petersburg, Florida, will allow the firm to accelerate the growth of early-stage companies in the area.

Here is the original post:
The View from ARK Invest: A Discussion with Simon Barnett and Ali Urman - Genetic Engineering & Biotechnology News

Posted in Biotechnology | Comments Off on The View from ARK Invest: A Discussion with Simon Barnett and Ali Urman – Genetic Engineering & Biotechnology News

Home :: National Institute for Biotechnology and Genetic Engineering

Highlights

Events and Activities

NIBGE Email

Welcome to NIBGE

PAEC has clear mandates on the safe use of modern sciences with an aim to improve the socio economic growth of the country. NIBGE is one of the main biotechnology institutes of the four bioscience centers of PAEC and was formally inaugurated by the President of Pakistan in 1994. It is also an affiliate center of ICGEB. The institute is a focal point of modern biotechnology and provides a technology receiving unit to help the development of country through applications of modern biotechnology and genetic engineering. The research programs at NIBGE are mainly aimed at improving agriculture, health, environment and industry and are supported by national and international financial grants. The institute research facilities include state of the art equipments supported by technical services, IT facility and a National Library for Biological Sciences. The institute now offers several services and marketable products. The educational programs leading to MPhil and PhD degrees have also been incorporated in the institutes mandate for the development of human resources in modern sciences.

Announcement

Featured News

Read the rest here:
Home :: National Institute for Biotechnology and Genetic Engineering

Posted in Biotechnology | Comments Off on Home :: National Institute for Biotechnology and Genetic Engineering

Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology – ETF Trends

Putnam Investments announced that on Friday, September 30, it will launch two new transparent, actively managed, equity exchange traded funds: the Putnam BDC Income ETF (NYSE Arca: PBDC), concentrating on business development companies (BDCs), and the Putnam BioRevolutionETF(NYSE Arca: SYNB), centered on companies operating at the intersection of technology and biology in the biology revolution.

PBDC will represent the first actively managed BDC ETF in the marketplace, investing in a host of BDC opportunities with an eye toward generating income for investors.

Putnam is excited to bring these two dynamic new strategies to market as we seek to address the long-term investment needs of advisors and their clients, said Robert L. Reynolds, president and CEO of Putnam Investments, in a news release. Our firm is focused on providing unique and differentiated offerings delivered through a variety of vehicles that tap Putnams deep investing expertise and exceptional research capabilities.

PBDC invests in exchange traded BDCs based in the U.S. and registered with the SEC. BDCs generally invest in, lend capital to, or provide services to privately held U.S. companies or thinly traded U.S. public companies. Putnam has managed a similar non-public BDC-focused strategy for nearly five years. The fund is managed by Michael Petro.

SYNB, meanwhile, invests in companies that seek to capitalize on the convergence of technological developments in the life sciences sector, including technology-enabling companies, synthetic biology companies, and companies that operate in industries that are likely to benefit from the biology revolution. The fund is managed by William Rives.

We have identified BDCs and advances in the biology sector as providing distinctive opportunities for investors in rapidly evolving sectors of the economy, added Carlo Forcione, head of product and strategy at Putnam Investments. Our new ETFs represent innovative, early-to-market offerings that will align well with the portfolio construction needs of our clients and the broader marketplace.

The new ETFs will join Putnams existing suite of four active ETFs that the firm launched in May 2021: the Putnam Focused Large Cap Growth ETF (NYSE Arca: PGRO), the Putnam Focused Large Cap Value ETF (NYSE Arca: PVAL), the Putnam Sustainable Future ETF (NYSE Arca: PFUT), and the Putnam Sustainable Leaders ETF (NYSE Arca: PLDR).

For more news, information, and strategy, visitVettaFi.

Read the rest here:
Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology - ETF Trends

Posted in Biotechnology | Comments Off on Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology – ETF Trends

The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Biotechnology Market Research Report by Technology (Cell-based Assays, Chromatography, and DNA Sequencing), Application, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.

The Global Biotechnology Market size was estimated at USD 876.74 billion in 2021, USD 1,023.15 billion in 2022, and is projected to grow at a CAGR 16.87% to reach USD 2,234.84 billion by 2027.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biotechnology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Biotechnology Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biotechnology Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biotechnology Market?

4. What is the competitive strategic window for opportunities in the Global Biotechnology Market?

5. What are the technology trends and regulatory frameworks in the Global Biotechnology Market?

6. What is the market share of the leading vendors in the Global Biotechnology Market?

7. What modes and strategic moves are considered suitable for entering the Global Biotechnology Market?

Market Dynamics

Drivers

Restraints

Opportunities

Challenges

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/ijpdlj

See the rest here:
The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 - ResearchAndMarkets.com - Business Wire

Posted in Biotechnology | Comments Off on The Worldwide Biotechnology Industry is Expected to Reach $2234 Billion by 2027 – ResearchAndMarkets.com – Business Wire

Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors – GlobeNewswire

Press release

Cambridge, MA U.S.A. (September 26, 2022) Allarity Therapeutics, Inc. (Nasdaq: ALLR) (Allarity or the Company), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP companion diagnostics for personalized cancer care, today announced the appointment of Jerry McLaughlin as a new member of its Board of Directors, effective October 1, 2022.

Mr. McLaughlin is a highly accomplished biotechnology executive with extensive experience in financing, drug development, licensing, commercialization, and product lifecycle management. Mr. McLaughlin is expected to serve on the compensation, and audit committees as an independent director.

I am delighted that Jerry has chosen to join Allaritys board at this crucial time in our evolution, said Dr. Duncan Moore, Allaritys Chairman of the Board. His operational experience in clinical stage therapeutic development and capital markets acumen will be of great value as we continue to implement the Companys combination therapy-focused strategy.

Mr. McLaughlin said: I firmly believe Allarity Therapeutics is in a unique position to become a leader within the personalized medicine space by developing novel combination oncology therapies together with the Companys unique DRP companion diagnostics. Allaritys recent strategic shift is aligned with the ongoing patient and market realities in oncology, as we continue to see substantially higher patient benefits with combination therapies. I look forward to supporting the CEO, Jim Cullem, and the rest of the Allarity team in unlocking both the clinical and commercial potential of this strategy.

Mr. McLaughlin has three decades of experience in leading operational and executive management roles. He made key contributions to significant life science milestones, including product launches, acquisitions, and financings. He is currently serving as CEO and Board Member of Life Biosciences, LLC, a development-stage biopharmaceutical company advancing therapeutics for patients with neurological and psychiatric diseases. Prior to serving in this role, he was President, CEO, and Member of the Board of Directors at Neos Therapeutics (acquired by Aytu BioScience.) Before joining Neos Therapeutics, he served as President, CEO, and Member of the Board of Directors at AgeneBio, Inc. Earlier in his career, he held corporate leadership roles at NuPathe, Inc., Endo Pharmaceuticals Inc., and Merck & Co., Inc. He received his B.A. from Dickinson College and his MBA from Villanova University in Pennsylvania.

About Allarity Therapeutics

Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer; dovitinib, a post-Phase 3 pan-tyrosine kinase inhibitor; and the European rights to IXEMPRA (Ixabepilone), a microtubule inhibitor approved in the U.S. and marketed by R-PHARM U.S. for the treatment of second-line metastatic breast cancer, currently in Phase 2 development in Europe for the same indication. Additionally, the Company has rights in two secondary assets: 2X-111, a liposomal formulation of doxorubicin in Phase 2 development for metastatic breast cancer and/or glioblastoma multiforme (GBM), which is the subject of discussions for a restructured out-license to Smerud Medical Research International AS; and LiPlaCis, a liposomal formulation of cisplatin and its accompanying DRP, being developed via a partnership with Chosa ApS, an affiliate of Smerud Medical Research International, for late-stage metastatic breast cancer. The Company is headquartered in the United States and maintains an R&D facility in Hoersholm, Denmark. For more information, please visit the Companys website at http://www.Allarity.com.

About the Drug Response Predictor DRP Companion Diagnostic

Allarity uses its drug-specific DRP to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high DRP score, the therapeutic response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA from patient biopsies. The DRP platform has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 37 out of 47 clinical studies that were examined (both retrospective and prospective), including ongoing, prospective Phase 2 trials of Stenoparib and IXEMPRA. The DRP platform, which can be used in all cancer types and is patented for more than 70 anti-cancer drugs, has been extensively published in peer reviewed literature.

Follow Allarity on Social Media

Facebook: https://www.facebook.com/AllarityTx/ LinkedIn: https://www.linkedin.com/company/allaritytx/ Twitter: https://twitter.com/allaritytx

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide Allaritys current expectations or forecasts of future events. The words anticipates, believe, continue, could, estimate, expect, intends, may, might, plan, possible, potential, predicts, project, should, would and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements related to clinical and commercial potential due to the Company advancing dovitinib in combination with another therapeutic candidate or other approved drug, any statements related to ongoing clinical trials for stenoparib as a monotherapy or in combination with another therapeutic candidate for the treatment of advanced ovarian cancer, or ongoing clinical trials (in Europe) for IXEMPRA for the treatment of metastatic breast cancer, and statements relating to the effectiveness of the Companys DRP companion diagnostics platform in predicting whether a particular patient is likely to respond to a specific drug. Any forward-looking statements in this press release are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to,the risk that results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive reviews of the data, and as more patient data become available, the risk that results of a clinical study are subject to interpretation and additional analyses may be needed and/or may contradict such results, the receipt of regulatory approval for dovitinib or any of our other therapeutic candidates or, if approved, the successful commercialization of such products, the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies will not be repeated or observed in ongoing or future studies involving our therapeutic candidates, and the risk that the current COVID-19 pandemic will impact the Companys current and future clinical trials and the timing of the Companys preclinical studies and other operations. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our Form S-1 registration statementon file with theSecurities and Exchange Commission, available at the Securities and Exchange Commissions website atwww.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Companys subsequent filings with theSecurities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

###

Company Contact:

Thomas JensenSenior V.P. of Investor Relationsinvestorrelations@allarity.com

Investor Relations:

Chuck PadalaLifeSci Advisors+1(646) 627-8390chuck@lifesciadvisors.comU.S. Media Contact:

Mike Beyer Sam Brown, Inc. +1 (312) 961-2502 mikebeyer@sambrown.com

EU Media Contact:

Thomas PedersenCarrotize PR & Communications +45 6062 9390tsp@carrotize.com

Read the rest here:
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors - GlobeNewswire

Posted in Biotechnology | Comments Off on Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors – GlobeNewswire